In addition, patients harboring the U2AF1 mutation showed inferior PFS in the higher risk groups (RAEB-1 or RAEB-2) defined by WHO 2008 criteria (P = 0.045; Fig. 3b). The gene discussed is U2AF1; the disease is myelodysplastic syndrome with excess blasts.